XAIR 0.35 Beyond Air, Inc.
| Range: | 0.296-2.61 | Vol Avg: | 539643 | Last Div: | 0 | Changes: | -0.01 |
| Beta: | -0.12 | Cap: | 0.02B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Jun 12 2018 | Empoloyees: | 107 | ||
| CUSIP: | 08862L103 | CIK: | 0001641631 | ISIN: | US08862L1035 | Country: | US |
| CEO: | Mr. Steven Adam Lisi | Website: | https://www.beyondair.net | ||||
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.
Stock Details
XAIR 1
Beyond Air price target lowered to $1 from $3.50 at Piper Sandler
Jason Bednar·Wed Aug 07 2024
Piper Sandler
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow